Amvuttra is used in adults to treat polyneuropathy (nerve damage) related to hereditary amyloid transthyretin-mediated (hATTR) amyloidosis. This is a rare genetic (inherited) condition that causes ...

Long-term treatment with patisiran (Onpattro) led to modest changes for people with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy, data from a global open-label extension (OLE ...

ATTR amyloidosis is an aggressive, rapidly progressing, debilitating and fatal disease, and the launch of Alnylam's earlier Onpattro (patisiran) in 2018 for polyneuropathy associated with the ...

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

Ionis Pharmaceuticals IONS incurred a loss of 66 cents per share for fourth-quarter 2024, which was narrower than the Zacks ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Previously known as primary amyloidosis, systemic amyloid light chain (AL) amyloidosis is the most common form of systemic amyloidosis in developed countries. Although occasionally localized and ...

Nexiguran ziclumeran is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM). The phase III MAGNITUDE study is ...